1. Scrip
  2. >>R&D

Denali Sees Some Early Progress With Fusion Protein For Hunter Syndrome

But Share Price Knocked Back

 
• By John Davis

Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.

hunter syndrome brain
• Source: Alamy

Denali Therapeutics Inc.’s brain-penetrating enzyme replacement therapy DNL310 (ETV:IDS) has shown beneficial clinical effects in children with Hunter syndrome (MPS II), in interim data from a Phase I/II study, although the performance of a new potential biomarker for the condition apparently disappointed some investors.

The South San Francisco, CA-based firm said it was excited about the results emerging from the study, which continue to validate the company’s blood-brain barrier technology, and was accelerating efforts to start a pivotal Phase II/III study in the first half of next year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D